We’ve previously highlighted psilocybin as an alternative treatment for various neuropsychiatric disorders, including anxiety, depression, and PTSD, along with legislative efforts at the state and federal levels to legalize and regulate the psychedelic drug. On March 12, 2025, New Mexico advanced its initiative to establish a therapeutic psilocybin program in the state.

By a bipartisan vote of 33-4, the New Mexico Senate passed Senate Bill 219, also known as the Medical Psilocybin Act, which now awaits a vote in the House of Representatives. If enacted, the bill would allow physicians to prescribe psylocybin to patients suffering from specific qualifying conditions such as major treatment-resistant depression, PTSD, substance use disorders, end-of-life care, and other conditions approved by the state’s Department of Health.

The bill defines psilocybin as “the naturally occurring psychedelic compound 4-phosphoryloxy-N,N-dimethyltryptamine, also known as 4-PO-DMT, and its pharmacologically active metabolite psilocin, 4-hydroxy-N,Ndimethyltryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin”. The bill proposes the establishment of a nine-member medical psilocybin advisory board to, among other things, “review and recommend to the [health] department for approval medical conditions that may benefit from the medical use of psilocybin” and “recommend formulation or preparation rules and dosage standards for psilocybin”. If the bill is enacted, New Mexico would join Oregon and Colorado as the only states to legalize the supervised use of psylocybin.